Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Public ClinicalTrials.gov record NCT06799247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Study identification
- NCT ID
- NCT06799247
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2025
- Primary completion
- Dec 29, 2026
- Completion
- Sep 29, 2027
- Last update posted
- Aug 31, 2026
2025 – 2027
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| A40 | Tucson | Arizona | 85718 | — |
| A13 | Carlsbad | California | 92011 | — |
| A46 | Los Angeles | California | 90095 | — |
| A14 | Orange | California | 92868 | — |
| A21 | Aurora | Colorado | 80045 | — |
| A50 | Washington D.C. | District of Columbia | 20007 | — |
| A48 | Maitland | Florida | 32751 | — |
| A10 | Tampa | Florida | 33612 | — |
| A53 | O'Fallon | Illinois | 62269 | — |
| A20 | Fairway | Kansas | 66205 | — |
| A16 | Lexington | Kentucky | 40536 | — |
| A38 | Boston | Massachusetts | 02111 | — |
| A12 | Amherst | New York | 14226 | — |
| A52 | New York | New York | 10027 | — |
| A47 | New York | New York | 10065 | — |
| A22 | Chapel Hill | North Carolina | 27599 | — |
| A39 | Charlotte | North Carolina | 28204 | — |
| A15 | Portland | Oregon | 97239 | — |
| A11 | Philadelphia | Pennsylvania | 19104 | — |
| A49 | Pittsburgh | Pennsylvania | 15213 | — |
| A43 | Houston | Texas | 77030 | — |
| A41 | Seattle | Washington | 98195 | — |
| A54 | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06799247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06799247 live on ClinicalTrials.gov.